An interventional study of Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread" and Active Control-Nutella hazelnut cocoa spread in Type1diabetes, sponsored by Rabin Medical Center. Recruiting at 1 site in Israel. Open to participants aged 18 Years to 35 Years. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by Rabin Medical Center · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center — 8 open to participants now, 8 under way, none of them phase 3. Diabetes Mellitus, Type 1 · Rabin Medical Center.
Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, this one is the 18th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2024, is one of 31 with no phase, and was the 38th registered.
3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →8 of the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center are open now, in 2 countries. Recruiting first, the newest first:
Rabin Medical Center · Sites in Israel, Slovenia
Ages 6–75
Rabin Medical Center · Sites in Israel
Ages 2–45 · Healthy volunteers
Rabin Medical Center · Sites in Israel
Ages 6–18
Rabin Medical Center · Sites in Israel
Ages 2–45 · Healthy volunteers
Rabin Medical Center · Sites in Israel
Ages 9 mo–5 yrs
By country, each count listing its studies:
Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.
This study: 18 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
42 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 40 across 2,824 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 30 across the 38 interventional studies, 10,150 across the 4 observational. Of the 31 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Rabin Medical Center is the lead sponsor of 393 studies on the registry; 30 are open to participants now.
2 of the studies in Diabetes Mellitus, Type 1 by Rabin Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04834518Rabin Medical CenterScreening for Islet Autoantibodies in the Israeli Paediatric General Population for Detection of Pre-symptomatic Type-1 Diabetes Mellitus | 2027-03-31 |
| NCT06687434Rabin Medical CenterCarb Counting vs. Simplified Qualitative Meal-Size Estimation | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 42 studies in Diabetes Mellitus, Type 1 by Rabin Medical Center, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Omega Galil has developed a novel fatty sweetener that allows the use of up to 80% less sugar (particularly sucrose) and yet achieves a natural sweet flavor, using a novel technology of milling the natural sucrose crystals together with oil and thus creating a micro-suspension of sugar in oil or fat. The suspension increases the surface area of the sugar particles and thus a lower quantity of sugar is required in order to reach an enhanced perception of sweetness at the sweet taste receptors in the mouth. Omega Galil provides fatty food products that use up to 80% less sucrose, while tasting as sweet as regular sugar sweetened foods, with no aftertastes of sugar substitutes, and no chemical modifications or additives.
Postprandial glucose (PPG) excursions in Type 1 Diabetes happen mainly due to a delay in subcutaneous insulin absorption and action, but also among other factors, depend on the meal composition. The glycemic index (GI) ranks foods based on acute glycemic response over a 2-h period of 50 g of available carbohydrates (CHO) of a test food compared with the reference standard glucose. Glycemic Load (GL) is a GI-weighted measure of carbohydrate content, which estimates the impact of carbohydrate intake using the GI while taking into account the amount of carbohydrates that are eaten in a serving. Several studies have demonstrated differences in PPG after consumption of low versus high GI meals, with rapid glucose spikes following high GI meals . Helping people with T1D achieve a diet with a lower glycemic load can improve both their quality of life and their diabetes-associated complications.
The proposed randomized, double blind, cross-over, active control, clinical trial aims to:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
Other: Omega Galil Hazelnut Chocolate Spread "O'Sweet Spread"
Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
Other: Active Control-Nutella hazelnut cocoa spread
Omega Galil O'Sweet hazelnut cocoa spread is composed of 8% sucrose, 26% MCT oil, 6% cocoa butter, 6% cocoa powder, 10% Hazelnut paste, 24% fibers, 13% rice flour. It contains a total of 27.3 gram carbohydrates/ 100gram, 520 kcals/100 grams, and very low estimated GL according to healthy adults
Also known as: "O'Sweet Spread"
Nutella hazelnut cocoa spread is composed of 56% sugar, 30% vegetable fat, 13% Hazelnut paste, milk powder (8.7%), and cocoa powder (7.4%), containing a total of 57.5 grams carbohydrates /100grams, 532 kcals/100 grams, and an estimated GL of 4
Also known as: Nutella hazelnut cocoa spread
Delta postprandial glucose level
The difference between pre-meal and peak postprandial glucose level in each of the two 2 hours' meal tests.
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Incremental area under the curve (iAUC)
Incremental area under the curve (iAUC) using continuous glucose sensor data \> 180 mg/dl between the beginning of the meal and 2 hours postprandial (defined as the postprandial period).
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Peak postprandial glucose level
The peak postprandial glucose level during the 2-hour postprandial period
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Time in range (TIR) of 70-180 mg/dl
Time in range (TIR) of 70-180 mg/dl during the postprandial period
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Percentage of subjects who reached the desired glucose target
The percentage of subjects who reached the desired glucose target (70-180 mg/dl) during the postprandial period (70% of the time)
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
The percentage of time spent above 180 mg/dl
The percentage of time spent above 180 mg/dl
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
The percentage of time spent above 250 mg/dl
The percentage of time spent above 250 mg/dl
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
The percentage of time spent above 350 md/dl
The percentage of time spent above 350 md/dl
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Labeled Magnitude Scale (gLMS)
Acceptance of the sweetness level Labeled Magnitude Scale (gLMS)
Time frame: first meal teat visit 1 (day 1) and second meal test visit 2 (2 weeks)
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2024 (actual). Primary completion is estimated for Apr 2024, 1 month after the start.
Of 852 non-industry interventional studies with no phase under Diabetes Mellitus, Type 1, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 37. This study's planned 1 month is below that.
Counting every sponsor, half of 957 studies reached it within 18 months; a quarter within 9 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.